RECURSION PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 560.08K shares, a 58.22% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 951.07K shares, a 37.85% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-06-30 was 1.71M shares, a 211.52% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-03-31 was 1.86M shares, a 42.52% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 5.08M shares, a 30.81% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 3.88M shares, a 19.43% decline from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 4.82M shares, a 19.72% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 4.03M shares, a 0.22% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 560.08K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 5.08M shares 10-K · filed 2026-02-25 |
| 2025-09-30 | 951.07K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 5.86M shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 1.71M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 5.60M shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 1.86M shares 10-Q · filed 2025-05-05 | 4.44M shares derived: sum of 4 quarters · filed 2025-05-05 |
| 2024-12-31 | 1.34M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | 3.88M shares 10-K · filed 2025-02-28 |
| 2024-09-30 | 689.95K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 3.82M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 549.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 4.70M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 1.30M shares 10-Q · filed 2024-05-09 | 5.54M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 1.27M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 4.82M shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 1.57M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 4.51M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 1.39M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 3.82M shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 582.39K shares 10-Q · filed 2023-05-08 | 3.83M shares derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | 963.06K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | 4.03M shares 10-K · filed 2023-02-27 |
| 2022-09-30 | 880.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 4.37M shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 1.40M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 3.70M shares derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | 780.46K shares 10-Q · filed 2022-05-10 | 3.08M shares derived: sum of 4 quarters · filed 2022-05-10 |
| 2021-12-31 | 1.31M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | 4.02M shares 10-K · filed 2022-03-23 |
| 2021-09-30 | 206.52K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | |
| 2021-06-30 | 782.47K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | |
| 2021-03-31 | 1.72M shares 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |